# Colorifix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/colorifix

- Industry: Materials
- Headquarters: Norwich, UK
- Website: www.colorifix.com
- Total disclosed funding: $46M
- Latest round: Series B (Dec 31, 2024)
- Investors on record: 11

## About

Colorifix Ltd is an innovative biotechnology company focusing on sustainable textile dyeing processes that minimize the environmental impact of traditional dyeing techniques.Founded in 2016 and headquartered in Norwich, UK, Colorifix specializes in biological dyeing solutions that utilize engineered microorganisms to produce natural pigments. The company has not undergone any significant operational pivots and focuses on serving textile manufacturers and dye houses globally. Colorifix has successfully raised GBP 18.000 mn in its latest funding round, SERIES B, on May 24, 2022, led by H&M Group Ventures, attracting various other investors. CEO Orr Yarkoni leads the company, which has engaged in 5 total deals since its inception.Colorifix specializes in a novel biological dyeing process that replaces traditional harmful chemicals used in textile dyeing with environmentally friendly alternatives. The company's core offerings revolve around engineered microorganisms, specifically bacteria or yeast, that produce vibrant pigments derived from various natural organisms, including plants, animals, and microbes. These engineered microbes are cultivated in fermentors using non-hazardous agricultural by-products, which act as growth mediums. The resultant biological dyes are then integrated into standard dyeing machines to color yarns, fabrics, and garments, maintaining industry quality standards while significantly minimizing environmental impact. Colorifix primarily serves textile manufacturers and dye houses in multiple geographical markets, notably in Europe and North America, where there is a growing demand for sustainable fashion solutions.Colorifix generates revenue through direct partnerships with textile mills and dye houses, who utilize their innovative dyeing technology. The company operates on a B2B model, where clients engage in contracts to incorporate Colorifix's biological dyeing solutions into their production processes. Revenue transactions occur as these manufacturers purchase access to the engineered microbe technology, ensuring a seamless integration into their existing dyeing operations. The pricing structure is based on the scale of dye production and the specific needs of each client, reflecting the customization and innovation involved in each partnership. Flagship offerings include the proprietary Colorifix biological dye solutions, which are marketed as premium alternatives to conventional dye methods, appealing to brands focused on sustainability and environmental responsibility.Following the recent funding round of GBP 18.000 mn on May 24, 2022, Colorifix plans to implement its technology into the supply chains of key players in the global fashion industry and expand its business further into Europe and Asia. The funding will support the development of upcoming products and enhancements to existing offerings, ensuring they meet the evolving needs of the market. The company is targeting completion of these initiatives by the end of 2023, aiming to solidify its presence in these regions and drive the adoption of sustainable dyeing practices.

## Funding rounds

- Series B, Dec 31, 2024, $21M — H&M Group Ventures, Sagana, Regeneration.VC, Goldwin Venture Partners, Youngone Holdings Co., Inter IKEA Group
- Series B, May 24, 2022, $23M — Cambridge Enterprise, H&M Group Ventures, Sagana, Regeneration.VC, PDS Ventures, SynBioVen, Bombyx Capital Partners AG
- Series A, Dec 14, 2018, $1.9M — Cambridge Enterprise, H&M Group Ventures, Sagana, Primera Impact

## Investors

- Cambridge Enterprise — Series A, Series B
- H&M Group Ventures — Series A, Series B
- Sagana (https://capitalatlas.ai/funds/sagana) — Series A, Series B
- Primera Impact — Series A
- Regeneration.VC (https://capitalatlas.ai/funds/regeneration-vc) — Series B
- PDS Ventures (https://capitalatlas.ai/funds/pds-ventures) — Series B
- SynBioVen (https://capitalatlas.ai/funds/synbioven) — Series B
- Bombyx Capital Partners AG (https://capitalatlas.ai/funds/bombyx-capital-partners-ag) — Series B
- Goldwin Venture Partners (https://capitalatlas.ai/funds/goldwin-venture-partners) — Series B
- Youngone Holdings Co. (https://capitalatlas.ai/funds/youngone-holdings-co) — Series B
- Inter IKEA Group — Series B